2VJ.F Ascletis Pharma Inc

Healthcare Biotechnology Frankfurt Exchange
0.5400 EUR
Close of Nov 12, 2026
0.4700 2.06
Market cap
EUR 565M
P/E
-
P/B
1.85x
ROE
-18.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 2VJ.F undervalued?

Graham number

The Graham number of Ascletis Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ascletis Pharma Inc fundamental analysis

No fundamental analysis for Ascletis Pharma Inc yet.

Ascletis Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC …

Full company profile